NPC-2014-GPOH-Registry

Author: Julia Dobke, erstellt am: 2015/02/16, Last modification: 2019/06/19

Title Multicentre registry for the treatment of the nasopharyngeal carcinoma in children and young adults
Disease Nasopharyngeal carcinoma
Type Registry
Problem / Objectives
  • Continuation of the good results of the trials NPC 1991 and NPC-2003-GPOH
  • Ongoing quality warranty by gathering of reference findings and collection of epidemiological data
  • Further evaluation of the value of PET-CT in correlation to MRT for the assessment of the remission
  • Continuation of the regime to reduce the radiation dose for patients with complete remission after neoadjuvant chemotherapy
  • Further evaluation of the value of virological markers
  • Collection of biological material (tumour, blood) for the support of essential accompanying scientific studies
Therapy / Study arms

Based on the results of the trial NPC-2003 the registry offers a recommendation for the treatment of the nasopharyngeal carcinoma. It corresponds to the state of the art for the treatment of the nasopharyngeal carcinoma

Stadium I: Radiotherapy 45Gy+14,4Gy; followed by off-label Interferon-therapy with Rebif®
Stadium II-IV (M0): Chemotherapy with 3 courses Cisplatin and 5-FU; depending of the response followed by radiotherapy with 45Gy+9,4Gy or 45Gy+14,4 Gy and parallel 2 courses chemotherapy with Cisplatin. Followed by off-label Interferon-therapy with Rebif®
Stadium IV (M1):Chemotherapy with 4 courses Cisplatin and 5-FU; radiation of the primary tumour with 45Gy+14,4Gy and the metatases following the recommendaton of the reference radiologist;, parallel to the radiation 2 courses chemotherapy with Cisplatin and T-Cell-therapy. Followed by off-label Interferon-therapy witht Rebif®

Inclusion Criteria
  • Primary diagnosis of nasopharyngeal carcinoma
  • Histology WHO Type II b or IIIa-b
  • Age up to 25 years
  • Reefernce histology
  • Written consent
Exclusion Criteria
  • Keratinizing squamous cell carcinoma (WHO Typ I)
  • Pretreatment with radio- or chemotherapy
  • Secondary malignancy
  • Pregnancy
  • Missing written informed consent for data transfer
Status December 2014
Principal Investigator Prof. Dr. med. R Mertens
E-Mail mailto:rmertens@ukaachen.de
Contact

Coordination

NameError: name 'adress' is not defined
Traceback (most recent call last):
File "/home/zope/virtualenv_zms3/lib/python2.7/site-packages/DocumentTemplate/DT_Try.py", line 149, in render_try_except
result = render_blocks(self.section, md)
File "/home/zope/virtualenv_zms3/lib/python2.7/site-packages/DocumentTemplate/DT_Let.py", line 77, in render
return render_blocks(self.section, md)
File "/home/zope/virtualenv_zms3/lib/python2.7/site-packages/DocumentTemplate/DT_Util.py", line 210, in eval
return eval(code, d)
File "<string>", line 1, in <expression>
NameError: name 'adress' is not defined

Assistence

Dr. med. Sabrina Franzen
Universitätsklinik der RWTH Aachen
Klinik für Kinder- und Jugendmedizin
Pauwelsstr. 30
52074 Aachen
Telefon +49 (0241) 80 89 222
Fax +49 (0241) 80 82 423
sfranzen@ukaachen.de

Link(s) Publications
Sponsoring „Hilfe für krebskranke Kinder“ e.V. Aachen